Supplemental Table 4 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Year: 2024
Type: supplementary-materials
Abstract: Supplemental Table 4: Baseline characteristics in HMA-naïve patients with HR-MDS treated with HMA plus venetoclax versus a contemporary HMA monotherapy cohort.
Authors: Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, Juan Jose Rodriguez-Sevilla, Sangeetha Venugopal, Samuel Urrutia, Guillermo Montalban-Bravo, Koji Sasaki, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Irene Ganan-Gomez, Tapan M. Kadia, Gautam Borthakur, Courtney D. DiNardo, Naval G. Daver, Elias J. Jabbour, Farhad Ravandi, Hagop Kantarjian, Guillermo Garcia-Manero
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4393383096